Thyroid Oncology
1Department of Endocrinology, Portuguese Cancer Institute, Lisboa, Portugal; Faculty of Medical Sciences, The New University of Lisbon, Lisboa, Portugal
2Section of Endocrinology, Hospital del Salvador, University of Chile, Santiago, Chile
3Department of Endocrinology, Fleury Medicine and Health, Cancer Institute of São Paulo (ICESP), University of São Paulo Medical School (USP), São Paulo, Brazil
4Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Thyroid Oncology
Description
Thyroid cancer is the unifying designation for malignancies deriving either from thyroid follicular cells (papillary, follicular, and anaplastic thyroid cancers) or from neuroendocrine “C” cells (medullary thyroid cancer). The reported incidence has been rising mainly due to the increase of papillary thyroid carcinoma. The causes of this increase are still controversial.
Thyroid cancer is mostly sporadic. However, evidence for a familial form is well documented. Whereas the susceptibility gene for hereditary medullary thyroid carcinoma is well defined, little is known about possible genes that may cause familial nonmedullary thyroid carcinoma.
Clinical outcome is extremely variable ranging from one of the most indolent to one of the most aggressive, among solid tumors. Therapeutic options for patients with progressive thyroid cancer are relatively ineffective.
Over the past two decades, the pathways involved in thyroid cancer development and progression have begun to be elucidated. Molecular-targeted therapies are currently being evaluated in clinical trials in both differentiated thyroid carcinoma and medullary thyroid carcinoma with promising preliminary results. Novel therapies are needed to improve dismal outcomes of anaplastic thyroid carcinoma.
We invite authors to submit original research and review articles on topics listed below. Papers that bridge across these areas are of special interest. Potential planned topics include, but are not limited to:
- Risk stratification in thyroid cancer
- Molecular markers in thyroid cancer
- Conventional management of thyroid cancer
- Molecular-targeted therapy in thyroid cancer
- Familial thyroid cancer
- Pediatric thyroid cancer
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jtr/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: